Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 561Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Zugelassene Systemtherapien in der Dermatologie
Monika Kleinhans,Carolin Funke-Lorenz,Joachim Dissemond
Der Hautarzt.2021;72(9)785
[DOI]
2Digital Transformation in Medical Affairs Sparked by the Pandemic: Insights and Learnings from COVID-19 Era and Beyond
Daniel Furtner,Salil Prakash Shinde,Manmohan Singh,Chew Hooi Wong,Sajita Setia
Pharmaceutical Medicine.2022;36(1)1
[DOI]
3Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas
Kathryn J. Hammer,Vanessa C. Copeland,Elizabeth T. Loggers,Seth M. Pollack,Michael J. Wagner,Lee D. Cranmer
American Journal of Clinical Oncology.2020;43(6)446
[DOI]
4Understanding the challenges and ethical aspects of compassionate use of drugs in emergency situations
PardeepKumar Goyal,Roli Mathur,Bikash Medhi
Indian Journal of Pharmacology.2020;52(3)163
[DOI]
5Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
Camille Taillé,Pascal Chanez,Gilles Devouassoux,Alain Didier,Christophe Pison,Gilles Garcia,Jeremy Charriot,Stéphane Bouée,Alina Gruber,Celine Pribil,Arnaud Bourdin,Marc Humbert
European Respiratory Journal.2020;55(6)1902345
[DOI]
6What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands
Eline M. Bunnik,Nikkie Aarts
BMC Medical Ethics.2019;20(1)1902345
[DOI]
7An overview of Compassionate Use Programs in the European Union member states
Gayathri Balasubramanian,Suman Morampudi,Pankdeep Chhabra,Arun Gowda,Behsad Zomorodi
Intractable & Rare Diseases Research.2016;5(4)244
[DOI]
8Expanding Patient Access to Investigational New Drugs
Gail A. Van Norman
JACC: Basic to Translational Science.2018;3(3)403
[DOI]
9Access to unlicensed medicines, who should pay when they are not provided for free?
Kieron David Lewis
Medicine Access @ Point of Care.2021;5(3)239920262110400
[DOI]
10Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing
Aaron S. Mansfield,Ben Ho Park,Michael P. Mullane
American Society of Clinical Oncology Educational Book.2018;5(38)873
[DOI]
11Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain)
Montse Gasol,Noelia Paco,Laura Guarga,Josep Ŕngel Bosch,Caridad Pontes,Mercč Obach
Journal of Clinical Medicine.2022;11(5)1353
[DOI]
12A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice
Beatrice Borelli,Gemma Zucchelli,Daniele Rossini,Chiara Cremolini,Carlotta Antoniotti,Roberto Moretto,Federica Marmorino,Camilla Colombo,Francesca Vannini,Laura Delliponti,Mario Spione,Elena Ongaro,Gianluca Masi,Isa Maura Brunetti,Elisabetta Pfanner,Lisa Salvatore,Alfredo Falcone
Colorectal Cancer.2018;7(1)CRC01
[DOI]
13International Country-Level Trends, Factors, and Disparities in Compassionate Use Access to Unlicensed Products for Patients With Serious Medical Conditions
Paul Aliu,Séverine Sarp,Ramona Reichenbach,Sigrid Behr,Paige Fitzsimmons,Mansurahmad Shamlajee,Surya Prakash Kola,Samantha Nunes Radimerski,Emil Scosyrev
JAMA Health Forum.2022;3(4)e220475
[DOI]
14Compassionate drug use: Current status in India
YashashriC Shetty,Smita Brahma,PS Manjesh
Perspectives in Clinical Research.2020;11(1)3
[DOI]
15Ethics framework for treatment use of investigational drugs
Jan Borysowski,Andrzej Górski
BMC Medical Ethics.2020;21(1)3
[DOI]
16Gene therapy companies have an ethical obligation to develop expanded access policies
Lisa Kearns,Carolyn Riley Chapman,Kenneth I. Moch,Arthur L. Caplan,Tom Watson,Andrew McFadyen,Pat Furlong,Alison Bateman-House
Molecular Therapy.2021;29(4)1367
[DOI]
17Gene therapy companies have an ethical obligation to develop expanded access policies
Ahmad Bechara,Rola Haroun
Molecular Therapy.2022;29(4)225
[DOI]
18Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology
Olga Löblová,Marcell Csanádi,Piotr Ozieranski,Zoltán Kaló,Lawrence King,Martin McKee
Health Policy.2019;123(7)630
[DOI]
19Educational needs, perception, and perspectives of oncologists regarding compassionate use programs in Asia
Manmohan Singh,Ankita Jain,Wade Fang,Peter Ong,Roberto Uehara,Jingming Zhong
Current Medical Research and Opinion.2021;37(9)1609
[DOI]
20Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari,Sagar Lonial,Tomer M. Mark,Amrita Y. Krishnan,Keith E. Stockerl-Goldstein,Saad Z. Usmani,Anil Londhe,Delores Etheredge,Sarah Fleming,Baolian Liu,Jon Ukropec,Thomas S. Lin,Sundar Jagannath,Ajay K. Nooka
Cancer.2018;124(22)4342
[DOI]
21Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Louise E. Curley,Maree Jensen,Zaheer-Ud-Din Babar,Sanya Ram
Cancer.2018;124(22)183
[DOI]
22Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016
Olga Löblová,Marcell Csanádi,Piotr Ozieranski,Zoltán Kaló,Lawrence King,Martin McKee
Health Policy.2019;123(8)713
[DOI]
23To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
Peter Martin,Andre Goy,Radhakrishnan Ramchandren,Lucille Ferrante,Anil Londhe,Tracy McGowan,Nancy L Bartlett
Journal of Oncology Pharmacy Practice.2019;25(4)1027
[DOI]
24Physician perspectives on compassionate use in pediatric oncology
Scott Moerdler,Lindy Zhang,Elena Gerasimov,Chong Zhu,Tamar Wolinsky,Michael Roth,Nancy Goodman,Daniel A. Weiser
Pediatric Blood & Cancer.2019;66(3)e27545
[DOI]
25Physician perspectives on compassionate use in pediatric oncology
Briana Hagelgans
Pediatric Blood & Cancer.2020;66(3)33
[DOI]
26Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV -1 in need of parenteral antiretroviral therapy
Ronald D'Amico,Santiago Cenoz Gomis,Riya Moodley,Rodica Van Solingen-Ristea,Bryan Baugh,Erika Van Landuyt,Veerle Van Eygen,Sherene Min,Amy Cutrell,Caroline Foster,Daniella Chilton,Sabine D. Allard,Annemiek Ruiter
HIV Medicine.2022;66(3)33
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal